罗红霉素辅助治疗复治肺结核疗效观察

A controlled clinical study on the efficacy of roxithromycin in the treatment of pulmonary tuberculosis

目的研究和评价罗红霉素辅助治疗复治肺结核疗效。方法将138例复治肺结核患者随机分为:治疗组70例,采用3PaZ(TH)L2VAKE+罗红霉素/3PaZ(TH)L2VE/9PaL2E方案化疗(Pa:力克肺疾,Z:吡嗪酰胺,TH:丙硫异烟胺,L:利福喷丁,V:左氧氟沙星,E:乙胺丁醇,AK:阿米卡星);对照组68例,采用3PaZ(TH)L2VAKE/3PaZ(TH)L2VE/9PaL2E方案化疗。结果完成疗程可评价疗效者133例,其中治疗组67例,对照组66例。治疗第1、3个月痰菌阴转率治疗组分别为33.3%和66.7%,对照组分别为10.7%和39.3%,差异有显著性(P<0.05)。治疗3个月时,治疗组和对照组显效率分别为34.3%和9.0%,治疗结束时治疗组和对照组显效率分别为62.9%和42.4%,差异有显著性(P<0.05)。无严重不良反应。结论罗红霉素辅助治疗复治肺结核,是一种安全、可靠的抗生素。

Objective To study and evaluate the efficacy of roxithmmyein In the treatment of pulmonary tuberculosis. Methods One hundred thirty-eight eases with re-treated pulmonary tuberculosis were randomly divided into a trial group [ 70 eases, treated with 3PaZ（TH） IaVAKE ＋ roxithromyein/3PaZ（TH） L2VE/9PaL2 E] and a control group [ 68 eases, treated with 3PaZ（TH） IaVAKE/3PaZ （TH） L2 VE/9PaL2 E ] The efficacy of 133 eases was available for evaluation when the course was completed （the trial group of 67 eases and the control group of 66 eases）. Results The sputum smear-negative conversion rates at the 1 st and the 3 rd month of the therapy were 33.3 % and 66.7 % in the trial group, and 10.7 % and 39.3 % in the eontrul group （P 〈 0. 05 ）. At the 3 rd month of the therapy, the X- ray salience resolution rates were 34. 3 % and 9.0%, respectively, in the trial and the control groups（ P 〈 0.01 ）. At the completion of the therapy, the X-ray salience resolution rates were 62. 9% and 42.2%, respectively, in the trial group and in the control groups （P 〈 0. 01 ）. Roxithromyein associated side effects were rare. Conclusion As an effective and safe antibiotic, mxithmmyein can be added to the standard chemotherapy for pulomonary tuberculosis.